| Título: | Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice—an updated analysis |
| Autores: |
Younus, J.; London Regional Cancer Program Vandenberg, T.; London Regional Cancer Program Jawaid, M.; Western University Jawaid, M.A.; Western University |
| Fecha: | 2012-11-29 |
| Publicador: | Multimed Inc. |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | febrile neutropenia; breast cancer; adjuvant chemotherapy |
| Descripción: | Chemotherapy in the adjuvant setting for early breast cancer (ebc) has improved disease-free and overall survival, with benefits extended to elderly patients and to those with lymph-node-negative pathology1,2. Recent clinical trials have largely supported the additional benefit of taxane therapy, including benefit in older patients3. The increase in the proportion of women treated and the improved survival mean that toxicities become increasingly important. One of the most serious acute toxicities is febrile neutropenia (fn). An updated U.S. Oncology trial report has demonstrated benefit in disease-free and overall survival for 4 cycles of docetaxel–cyclophosphamide (tc) chemotherapy over doxorubicin cyclophosphamide chemotherapy and has also reported acceptable toxicity, with a fn rate of 5%4. The tc regimen has become very popular in Ontario, particularly in older age groups who are at increased risk of cardiotoxicity with anthracyclines and in patients eligible for trastuzumab5. We previously published our experience with ebc patients treated with tc chemotherapy and the incidence of fn6. Here, we present our updated and expanded data examining the incidence of fn related to the use of tc chemotherapy in the adjuvant setting in ebc at the London Regional Cancer Program. |
| Idioma: | Inglés |
1 Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind por Sagar, Stephen,Dryden, Trish; Centre for Applied Research, Centennial College,Wong, Raimond K; McMaster University, Departments of Medicine and Oncology | 6 |
2 Chinese Medicine and Biomodulation in Cancer Patients (Part Two) por Sagar, Stephen M,Wong, Raimond K | 7 Cord stem-cell transplantation in Ontario: do we need a public bank? por Gassas, A.; the Hospital for Sick Children, Toronto |
3 Integrating Science and Human Values for Cancer Patient Care por Sutcliffe, Simon B.; BC Cancer Agency | 8 Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis por Szwajcer, D.; University of Manitoba,Czaykowski, P.; University of Manitoba,Turner, D.; CancerCare Manitoba |
4 Conservative Treatment of Invasive Bladder Cancer por Souhami, Luis; McGill University,Rene, Nicholas,Cury, Fabio Biagini | 9 Liver transplantation for symptomatic liver metastases of neuroendocrine tumours por Chan, G.; Hôpital Maisonneuve-Rosemont
Université de Montréal,Kocha, W.,Reid, R.,Taqi, A.,Wall, W.,Quan, D. |
5 A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital por Chin, S. N.,Wang, L.,Moore, M.,Sridhar, S. S.; University of Toronto | 10 What is the optimal management of dysphagia in metastatic esophageal cancer? por Cavallin, F.; Veneto Institute of Oncology,Scarpa, M.; Veneto Institute of Oncology,Cagol, M.; Veneto Institute of Oncology,Alfieri, R.; Veneto Institute of Oncology,Castoro, C.; Veneto Institute of Oncology |